Cabinet approves signing of MoU between India, Suriname in field of medicines regulation

The parties recognize the importance of developing close cooperation and exchanging information in the field of the regulation of medicines in accordance with their respective laws and regulations and reach the following understandings:

• to accept Indian Pharmacopoeia (IP) as a book of standards for medicines in Suriname so as to ensure quality of medicines being manufactured and/or imported in Suriname;
• to accept the Certificate of Analysis issued by Indian manufacturers per IP and to do away with requirement of duplicate testing of the medicines in Suriname;
• to get IPRS and Impurity standards from IPC at reasonably low cost to be used during the quality control analysis;
• to have better scope for development of generic medicines and contributing to availability of affordable medicines in Suriname;
• to promote an understanding of pharmacopoeia in regulatory framework, requirements and processes;
• to facilitate the exchange of information and documentation relating to the development of monographs of IP;
• to enhance the ability of regulatory authorities in the provision of their services relating to or in connection with public health, to meet the needs of their respective population;
• to explore opportunities for technical cooperation in areas of mutual benefit in the development of monographs and future technologies.

The Memorandum of Understanding will facilitate export of medical products leading to foreign exchange earnings. This would be a step towards an Atmanirbhar Bharat.

International recognition of the Indian pharmacopoeia! Standards has several benefits to the Indian pharmaceutical sector. These include:

• It would boost the export of Indian pharmaceutical products to these countries as it would remove double regulation, duplication in testing and post importation checks. Indian drug exporters would thus, gain a competitive edge and trade would become more remunerative.
• Further, importing nations would gain access to quality Indian medical products at affordable prices.
• Manufacturers in importing countries would have better scope for development of generic medicines contributing to availability of affordable medicines to their citizens.
• The various reference standards and impurity standards would become available to these manufacturers at a reasonable cost.

Convergence in the regulatory practices could help in increasing export of medicines from India and consequentially help in better employment opportunities for educated professionals in the Pharmaceutical sector.

The Indian Pharmacopoeia (IP) is officially recognized by five (5) countries: Afghanistan, Ghana, Nepal, Mauritius and the Republic of Suriname. The Ministry seeks to expand the nations which recognize the IP.